CRT consisted of concomitant cisplatin (3 doses of 100 mg/m 2 every 3 weeks or 7 doses of 40 mg/m 2 every week) and radiotherapy (70 Gy in 35 fractions). A single dose of durvalumab (1500 mg) was ...

Sevabertinib produced “robust and durable” responses in patients with HER2-mutant NSCLC, whether they were previously treated or untreated in the advanced setting, according to Xiuning Le, MD, PhD.

Disitamab vedotin plus toripalimab improved progression-free survival and overall survival when compared to chemotherapy.

Consistently reaching guidelines at moderate levels over three decades associated with significant reduction in DSC risk.

A systematic review with meta-analysis compared single- versus multi-port robotic approaches in prostate and renal surgery.

Researchers sought to determine whether survival outcomes for patients with early breast cancer was better with NACT or ACT when pCR was not achieved.

The approval for HR-SMM was based on data from the phase 3 AQUILA study, which evaluated Darzalex Faspro in adults aged 31 years and older with HR-SMM.

Study reveals 5.05 percent of individuals carry pathogenic/likely pathogenic variants in in large, unselected U.S. population.

Researchers sought to determine whether zanubrutinib would be effective for patients with CLL/SLL who were intolerant to other BTK inhibitors.

No differences seen among one-, two-, and three-year interval cancer predictions, age quartiles, or breast densities.

Recognizing these differences underscores the importance of age-tailored supporting care and ongoing assessment in the early-onset NETs patient population,” said Udhayvir Singh Grewal, MD.

Rates of overall survival, prostate cancer-specific death, and distant metastasis were similar in patients who received prophylactic whole pelvic radiotherapy compared to those who received ...